We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease.
- Authors
Thariat, Juliette; Etienne-Grimaldi, Marie-Christine; Launay-Vacher, Vincent; Soto-Matos, Arturo; Fernandez-Teruel, Carlos; Ghafari, Thomas; Marcy, Pierre-Yves; Milano, Gérard; Renée, Nicole; Gastaud, Lauris; Thyss, Antoine
- Abstract
Purpose: The pharmacokinetics of trabectedin has never been reported in patients with impaired renal function or in patients on hemodialysis. Methods: We examined trabectedin PK in a patient on hemodialysis, starting trabectedin therapy at a standard dose for recurrence of a retroperitoneal myxoid liposarcoma that had occurred under immunosuppressive drugs for kidney transplant. Results: As compared with a population with normal renal function, the study patient presented a higher C and AUC, with lower clearance, terminal half-life, and volume of distribution. The low dialysis clearance, accounting for a minor part of the total body clearance and the absence of detectable trabectedin in the dialysate samples, suggests that hemodialysis does not efficiently clear trabectedin. Trabectedin tolerance was good. Conclusions: This case reports for the first time the feasibility of trabectedin therapy in a hemodialyzed patient. Given the rising incidence of cancer in patients with end-stage renal disease, it is crucial to provide data that improve the management of anticancer drugs in dialyzed patients.
- Subjects
PHARMACOKINETICS; HEMODIALYSIS; TREATMENT of chronic kidney failure; KIDNEY transplantation; CANCER patients; IMMUNOSUPPRESSIVE agents; CANCER relapse
- Publication
Cancer Chemotherapy & Pharmacology, 2011, Vol 68, Issue 5, p1363
- ISSN
0344-5704
- Publication type
Article
- DOI
10.1007/s00280-011-1718-5